EGFR and non-small cell lung carcinoma: Our previous study demonstrated that the activation of AXL was required for the epithelial-mesenchymal transition and promoted erlotinib resistance in non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)14.